Coronary Artery Disease. Atherosclerotic heart disease of native coronary artery
Conditions
Interventions
Intervention 1: Intervention group: Curcumin 500 mg capsules - 3 capsules per day - for 40 days - Karen Pharmaceutical Company. Intervention 2: Control group: 500 mg capsule placebo - 3 per day - for
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients with coronary artery disease, who have at least one artery more than 70% blocked and confirmed by the cardiologist. Patients are willing to participate in the study
Exclusion criteria
Exclusion criteria: Smoking Continuous use of any antioxidant supplements such as vitamin E, vitamin C and selenium in the last month Cancer Existence of any change in the disease treatment plan, such as a change in the type and dose of lipid-lowering drugs or surgery Unwillingness to cooperate in the study The presence of advanced kidney disease Autoimmune and infectious diseases Pregnancy and breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Very Late Antigen-4. Timepoint: before the start of the study and 40 days after the start. Method of measurement: Flow cytometry.;P-selectin. Timepoint: before the start of the study and 40 days after the start. Method of measurement: Flow cytometry.;Interleukin-6. Timepoint: before the start of the study and 40 days after the start. Method of measurement: Elisa.;Tumor Necrosis Factor-Alpha. Timepoint: before the start of the study and 40 days after the start. Method of measurement: Elisa.;Macrophage-1 antigen. Timepoint: before the start of the study and 40 days after the start. Method of measurement: Flow cytometry.;Lymphocyte Function-Associated Antigen-1. Timepoint: before the start of the study and 40 days after the start. Method of measurement: Flow cytometry.;Endothelial Nitric Oxide Synthase. Timepoint: before the start of the study and 40 days after the start. Method of measurement: Polymerase chain reaction.;Intercellular Adhesion Molecule-1. Timepoint: before the start of the study and 40 days after the start. Method of measurement: Flow cytometry.;Vascular Cell Adhesion Molecule-1. Timepoint: before the start of the study and 40 days after the start. Method of measurement: Flow cytometry.;Platelet-Monocyte Aggregates. Timepoint: before the start of the study and 40 days after the start. Method of measurement: Flow cytometry.;Platelet-Neutrophil Aggregates. Timepoint: before the start of the study and 40 days after the start. Method of measurement: Flow cytometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohsen Hamidpoor
Shahid Beheshti University of Medical Sciences
Outcome results
None listed